

Contents lists available at [ScienceDirect](http://ScienceDirect.com)

## Clinical Microbiology and Infection

journal homepage: [www.clinicalmicrobiologyandinfection.com](http://www.clinicalmicrobiologyandinfection.com)

## Consensus statement

Consensus numbering system for the rifampicin resistance-associated *rpoB* gene mutations in pathogenic mycobacteriaE. Andre<sup>1,2,3,\*</sup>, L. Goeminne<sup>1</sup>, A. Cabibbe<sup>4</sup>, P. Beckett<sup>5,6</sup>, B. Kabamba Mukadi<sup>1,2</sup>, V. Mathys<sup>7</sup>, S. Gagneux<sup>8,9</sup>, S. Niemann<sup>6,10</sup>, J. Van Ingen<sup>2,11</sup>, E. Cambau<sup>3,11,12</sup><sup>1</sup> Pôle de Microbiologie Médicale, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium<sup>2</sup> Microbiology Unit, Cliniques Universitaires Saint-Luc, Brussels, Belgium<sup>3</sup> European Society for Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Mycobacterial Infections (ESGMYC), ESCMID, Basel, Switzerland<sup>4</sup> Emerging Bacterial Pathogens Unit, Tuberculosis Supranational Reference Laboratory (SRL), IRCCS San Raffaele Scientific Institute, Milano, Italy<sup>5</sup> Molecular and Experimental Mycobacteriology Group, Research Center Borstel, Borstel, Germany<sup>6</sup> German Center for Infection Research, Borstel Site, Borstel, Germany<sup>7</sup> National Reference Laboratory for Tuberculosis and Mycobacterial Diseases, Scientific Institute of Public Health (WIV-ISP), Brussels, Belgium<sup>8</sup> Swiss Tropical & Public Health Institute, Basel, Switzerland<sup>9</sup> University of Basel, Basel, Switzerland<sup>10</sup> Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands<sup>11</sup> APHP, Hôpital Lariboisière, Laboratory of Bacteriology, National Reference Center for Mycobacteria and Antimycobacterial Resistance, Paris, France<sup>12</sup> University Paris Diderot, INSERM IAME UMR1137, Sorbonne Paris Cité, Paris, France

## ARTICLE INFO

## Article history:

Received 29 July 2016

Received in revised form

12 September 2016

Accepted 12 September 2016

Available online xxx

Editor: F. Allerberger

## Keywords:

*Mycobacterium kansasii**Mycobacterium leprae**Mycobacterium tuberculosis**rpoB*

Numbering system

Resistance

Rifampicin

Rifampin

## ABSTRACT

The *rpoB* gene codes for the RNA polymerase  $\beta$  subunit, which is the target of rifampicin, an essential drug in the treatment of tuberculosis and other mycobacterial infections. This gene is present in all bacteria, but its length and nucleotide sequence vary between bacterial species, including mycobacteria. Mutations in the *rpoB* gene alter the structure of this protein and cause drug resistance. To describe the resistance-associated mutations, the scientific and medical communities have been using, since 1993, a numbering system based on the *Escherichia coli* sequence annotation. Using *E. coli* reference for describing mutations in mycobacteria leads to misunderstandings, particularly with the increasing use of whole genome sequencing, which brought an alternative numbering system based on the *Mycobacterium tuberculosis* *rpoB* sequence. We propose using a consensus numbering system for the reporting of resistance mutations based on the reference genomes from the species interrogated (such as strain H37Rv for *M. tuberculosis*). This manuscript provides the necessary figures and tables allowing researchers, microbiologists and clinicians to easily convert other annotation systems into one common language. **E. Andre, CMI 2016;■:1**

© 2016 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Introduction

Rifampicin, also named rifampin in the USA, is the key drug of the first-line treatment regimen for tuberculosis (TB), a disease affecting 9.6 million persons per year [1]. Multidrug-resistant TB (MDR-TB), defined as disease caused by *Mycobacterium tuberculosis* complex strains resistant to rifampicin and isoniazid, requires prolonged and

more complex administration of alternative treatment regimens including second-line anti-TB drugs, and is associated with poorer treatment outcome [2,3]. Isoniazid-resistance is caused by different mutations affecting different genes [4], but the molecular basis of RIF resistance is simpler, as virtually all resistant strains present a mutation in the *rpoB* gene, and 95% of these are located within a small 81-bp region named the rifampicin-resistance determining region (RRDR) [5]. Consequently, molecular assays were easily developed to detect rifampicin resistance, and several commercial kits are now available and used worldwide [6–8]. Furthermore, molecular detection of rifampicin resistance is used as a surrogate

\* Corresponding author.

E-mail addresses: [emmanuel.andre@uclouvain.be](mailto:emmanuel.andre@uclouvain.be), [emmanuel.andre@outlook.be](mailto:emmanuel.andre@outlook.be) (E. Andre).<http://dx.doi.org/10.1016/j.cmi.2016.09.006>1198-743X/© 2016 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

marker of MDR-TB in many countries, since <10% of rifampicin-resistant cases are not resistant to isoniazid [9–11]. The different species of the *M. tuberculosis* complex present similar resistance mutations [12–16].

Mutations in the *rpoB* gene are also associated with rifampicin resistance among other mycobacterial species, such as in *Mycobacterium leprae* causing leprosy [17,18] and *Mycobacterium kansasii* causing mainly respiratory infections in immunocompetent patients with also disseminated infections in immunocompromised patients [19]. Rifampicin resistance in *M. leprae* was described as associated with dapson resistance in patients with MDR-leprosy. For these leprosy cases, the standard treatment regimen needs to be switched to a 2-year treatment combining daily second-line agents such as fluoroquinolones [20]. In *M. kansasii*, rifampicin is also a key component of treatment. Here *rpoB* gene mutations also lead to rifampicin resistance [19] and the need for alternative regimens [21].

Rifampicin resistance is caused by a structural alteration in the RNA polymerase  $\beta$  subunit, an enzyme coded by the *rpoB* gene. This mechanism was first described in 1981 for *Escherichia coli* [22,23], and it is therefore not specific to mycobacteria, although the clinical utility of *rpoB* mutations characterization is more important for TB and leprosy than for any other bacterial infections [24].

It was only in 1993 that Telenti *et al.* first suggested that rifampicin resistance in *M. tuberculosis* complex was associated with mutations in the *rpoB* gene, and observed a high similarity of the amino acids coded between several bacterial species including *E. coli*, *M. tuberculosis* complex and *M. leprae* [5]. Since the mutations described in that work were identified in an *rpoB* region that aligned with the RRDR of *E. coli*, Telenti *et al.* proposed an annotation system based on the *E. coli* genetic sequence. The authors probably underestimated how the diversity of the *rpoB* nucleotide sequence would later affect our ability to correctly report single nucleotide mutations causing amino acid substitutions [25–27]. Furthermore, although the authors recognized that resistance mutations may be located outside the RRDR, they did not pay attention to the low similarity between *E. coli* and *M. tuberculosis* complex in *rpoB* outside the RRDR. The existence and epidemiological importance of these ‘non-RRDR’ resistance mutations was later confirmed [28–30]. Nevertheless, this annotation system was rapidly adopted [31] and is still often used today for *M. tuberculosis* complex [32,33], *M. leprae* [34,35] and *M. kansasii* [19,36]. It was only recently that authors started using a species-specific numbering system [29,37–39]. This has caused some confusion because the same mutations are now named differently depending on the author, the year and the journal that published the work. For *M. leprae*, *rpoB* mutations were numbered first according to the gene sequence of *M. leprae rpoB* gene cloned in a cosmid, where the codon 425 corresponds to the codon 531 in *E. coli* and this was used to establish the WHO resistance surveillance network [40–42]. More recently, this expert group decided to switch to the numbering system of the *M. leprae* genome taking as a reference the genome sequence of the Tamil Nadu (TN) strain [37,43,44].

In this manuscript, we discuss the limitations of the traditional numbering system and propose to shift towards a more natural numbering system based on the mycobacterial reference sequences. This should allow better communication between laboratories, especially at a time when whole genome sequencing is becoming the standard for detecting drug resistance [39], improved disease surveillance [45,46] and faster spreading of scientific knowledge in the medical community.

### Diversity of *rpoB* numbering systems

Among *M. tuberculosis* complex, *M. leprae* and *M. kansasii*, the nucleotide similarity lies between 86% and 88% for the entire *rpoB*

gene and is slightly higher in the 81-bp RRDR (between 88.9% and 92.6%). The similarity of these mycobacteria with *E. coli* is less (47% and 74% for the *rpoB* gene and the RRDR respectively) [47].

Furthermore, the *rpoB* genes of *E. coli*, *M. tuberculosis* complex, *M. leprae* and *M. kansasii* differ in length (4029, 3519, 3537 and 3540 base pairs, respectively). These differences explain the variable shift between the *E. coli*-based annotation and the mycobacterial sequence-based numbering systems. At present, resistance mutations outside the RRDR have only been characterized for *M. tuberculosis* complex. This situation leads to an even more complex situation, as the shift from the *E. coli* numbering system to the *M. tuberculosis* complex numbering system is different depending on the location of the resistance mutation (i.e. +24 for the *M. tuberculosis* complex codon 170, and –81 for the other codons of interest).

Table 1 and Fig. 1 represent the codons that are most frequently associated with resistance mutations across the three mycobacterial species. *Mycobacterium tuberculosis* complex and *E. coli* present identical amino-acids only for eight of the nine codons, and not nine as initially suggested by Telenti *et al.* [5]. Only three of the nine codons show the same sequence.

### Reporting systems derived from the use of commercial assays

The commercial assays have developed several mutation detection systems as an alternative to gene sequencing. These assays report rifampicin resistance based on the detection of mutations in the wild-type (WT) sequence of the RRDR by molecular beacons [48,49] or hybridization [8,37,50]. These tests include probes that bind to WT sequences (Xpert MTB/RIF (*M. tuberculosis*/rifampicin), Cepheid), eventually combined with additional probes binding to mutated sites (line probe assays InnoLipa RifTB, InnoGenetics, Ghent, Belgium; GenoType MTBDRplus and GenoType lepraeDR, Hain Lifescience, Nehren, Germany), so silent mutations or mutations not associated with resistance can occasionally generate false-positive results [50–54].

The reporting format of these commercial assays can be ‘matched’ with the specific sequence covered by each probe (Xpert MTB/RIF), or the combination of WT and mutation bands (MTBDRplus, lepraeDR) as illustrated in Fig. 2.

In practice, the majority of *rpoB* mutations are located at *M. tuberculosis* complex codons 435, 445 and 450 (also named 516, 526 and 531, respectively, using the *E. coli* numbering system) and at codons 456 and 441 in *M. leprae*. As an example, in the presence of the mutation Ser450Leu, the Xpert MTB/RIF assay will report a negative ‘Probe E’, signing the presence of a mutation located between positions 447 and 452. For the same mutation, the MTBDRplus V2.0 assay will report a negative ‘WT8’ band associated with a positive ‘MUT3’ band. Although complex laboratory networks generally use a combination of these tests, the concordance between the results of each test is rarely verified in routine conditions because of the difficulties in comparing between the numbering systems. The number of commercial assays available for TB diagnostics and detection of rifampicin resistance will increase in the future [55], and each of these tests will probably come with its own reporting format. If this is the case, the efforts required for understanding and solving discordant results will increase further [32].

### Consequences of different coexisting numbering systems


The sequencing methods used to identify mutations are currently shifting from traditional Sanger sequencing to whole genome sequencing [56,57]. Although both methods are used today and will continue to coexist for some years, high-throughput sequencing technologies present multiple advantages including

**Table 1**


Conversion table between the two co-existing numbering systems for the most frequent *rpoB* mutations associated with rifampicin resistance among *Mycobacterium tuberculosis* complex, *Mycobacterium leprae* and *Mycobacterium kansasii*

<i>M. tuberculosis</i> H37Rv (GenBank AL123456)		<i>M. leprae</i> TN (GenBank AL583923)		<i>M. kansasii</i> ATCC 12478 (GenBank CP006835)		<i>Escherichia coli</i> (GenBank V00339)	
WT nucleotide sequence (amino acid)	Codon position (conversion from <i>E. coli</i> numbering)	WT nucleotide sequence (amino acid)	Codon position (conversion from <i>E. coli</i> numbering)	WT nucleotide sequence (amino acid)	Codon position (conversion from <i>E. coli</i> numbering)	WT nucleotide sequence (amino acid)	Codon position
GTC (Val)	170 (+24)					GTT (Val)	146
GGC (Gly)	426 (–81)	GGC (Gly)	432 (–75)			GTT (Gly)	507
CTG (Leu)	430 (–81)	CTG (Leu)	436 (–75)			CTG (Leu)	511
CAA (Gln)	432 (–81)	CAG (Gln)	438 (–75)	CAG (Gln)	442 (–71)	CAG (Gln)	513
GAC (Asp)	435 (–81)	GAT (Asp)	441 (–75)	GAC (Asp)	445 (–71)	GTC (Val)	516
CAC (His)	445 (–81)	CAC (His)	451 (–75)	CAC (His)	455 (–71)	CAC (His)	526
TCG (Ser)	450 (–81)	TGC (Ser)	456 (–75)	TCG (Ser)	460 (–71)	TCC (Ser)	531
CTG (Leu)	452 (–81)	CTG (Leu)	458 (–75)			CTC (Leu)	533
ATC (Ile)	491 (–81)					ATC (Ile)	572

WT, wild-type. The homology in regard to the nucleotide and the amino acid sequences of the different mycobacteria and *E. coli* is highlighted in green. Differences are highlighted in red.



**Fig. 1.** (a) Alignment of the nucleotide sequences for the *rpoB* genes of *Escherichia coli*, *Mycobacterium tuberculosis* H37Rv (MTB), *Mycobacterium leprae* TN (ML) and *Mycobacterium kansasii* ATCC 12478 (MK). Rifampicin-resistance-determining region (RRDR) is highlighted in yellow. Red boxes show rifampicin resistance mediating mutation outside the RRDR. (b) Alignment of 81-bp RRDR of *E. coli*, *M. tuberculosis* complex, *M. leprae* and *M. kansasii*. Bars above the nucleotide sequences indicate the position of the seven codons frequently associated with rifampicin resistance, using the annotation system specific to each species. Nucleotide and amino acid differences are highlighted. Graph created using GENEIOUS, Biomatters, version 9.1).



**Fig. 2.** (a) Alignment of *Mycobacterium tuberculosis* complex rifampicin-resistance-determining region (RRDR) sequence with the targets of Xpert MTB/RIF and the MTBDRplus V2.0 commercial assays. The red bars represent the location of the most common codons associated with rifampicin resistance conferring mutations. The orange bars indicate the regions covered by the five probes of the Xpert MTB/RIF assay. The green bars represent the regions covered by the eight wild-type (WT) and four mutation bands of the GENOTYPE MTBDRPLUS V2.0 assay. (b) Alignment of *Mycobacterium leprae* RRDR sequence with the targets of the LepaeDR commercial assay. The blue bars represent the location of the codons associated with rifampicin resistance conferring mutations, the four WT bands and the two mutation bands. Graph created using GENEIOUS, Biomatters, version 9.1.

the ability to sequence simultaneously several genes associated with antimicrobial resistance. The inherent principles of sequencing require the use of an annotation system based on a consensus sequence, and starting at the beginning of each gene. Therefore, using *E. coli* as a reference sequence for *M. tuberculosis* complex and *M. leprae* is not reasonable, and hampers the necessity to correctly and precisely annotate genetic sequences and identify drug resistance-conferring mutations.

One example of how the use of different annotation systems can lead to major misunderstandings is the recent report from Swaziland. The authors reported that approximately one-third of the rifampicin-resistant *M. tuberculosis* complex strains were associated with the Ile491Phe mutation, a mutation that was supposedly never reported before, at least based on the *M. tuberculosis* complex numbering system [29]. However, this mutation is equivalent to Ile572Phe in the *E. coli* numbering system, a mutation that was described in rifampicin-resistant *M. tuberculosis* complex strains from many countries [58–63]. Sanchez-Padilla *et al.* used the *M. tuberculosis* complex-based annotation system, despite the fact that this denomination is almost non-existent in the scientific literature.

## Perspectives

The characterization of the *rpoB* gene in *M. tuberculosis* complex strains, including the precise localization of mutations conferring rifampicin resistance, is probably one of the most common molecular biology analyses performed for clinical purposes worldwide. Unfortunately, a standardized reporting format cannot be obtained because of the coexistence of different numbering systems used by commercial and non-commercial assays targeting this gene.

There are three main reasons why the *E. coli* and the device-specific numbering systems should be changed to one standardized system based on the sequence of the reference strain of each species, namely H37Rv (GenBank reference AL123456) for

*M. tuberculosis* complex, *M. leprae* Tamil Nadu (GenBank reference AL583923) for *M. leprae* and *M. kansasii* ATCC 12478 (GenBank reference CP006835) for *M. kansasii*. First, although the homology between *E. coli* and *M. tuberculosis* complex is relatively high in the RRDR, it is significantly lower for the rest of the *rpoB* gene. Therefore, although the correspondence between the *E. coli* and *M. tuberculosis* complex numbering systems is relatively easy within the hotspot region (the difference is 81 codons), such a 'simple conversion' does not work when looking at a resistance mutation located outside this specific region (the difference between the *M. tuberculosis* complex codon 170 and its equivalent in the *E. coli* genome is 24) [28,64]. Second, the sequencing method used to identify mutations is currently shifting from traditional Sanger sequencing methods to whole genome sequencing. As the genome of *M. tuberculosis* complex reference strain H37Rv is standard strain used worldwide [65], any variant numbering nomenclature should be based on this sequence [29,39,56]. Such revision has been previously proposed for the *gyrB* gene associated with fluoroquinolone resistance, for which four different reporting systems have been used, resulting in mutation location discrepancies [66]. Finally, many of the *rpoB* mutations reported in clinical strains so far have distinctive characteristics in conferring phenotypic resistance, including varying cross-resistance to rifabutin. Therefore, a precise nomenclature for the location of the mutations is essential from a laboratory diagnostic perspective, especially for the development of individualized treatment regimens [25,32].

Accordingly, the use of divergent numbering systems for *rpoB* mutations generates risks related to miscommunication and delays the transfer of scientific knowledge into clinical care.

The aim of this manuscript is to facilitate the shift towards this universal annotation system, including the necessary figures and tables allowing researchers, microbiologists and clinicians to easily 'translate' other annotation systems into one common language.



## Transparency Declaration

The authors declare no conflict of interest. No external funding was received for this manuscript.

## Acknowledgements

This consensus was initially drafted by EA, LG and EC. Known experts in the field were later approached to comment and complete the manuscript. The authors would like to thank Dr Armand Van Deun for his advice during the process of writing this manuscript.

## References

- [1] WHO. Global Tuberculosis Report. Geneva: WHO; 2015.
- [2] Villarino ME, Geiter LJ, Simone PM. The multidrug-resistant tuberculosis challenge to public health efforts to control tuberculosis. *Public Health Rep* 1992;107:616–25.
- [3] Park MM, Davis AL, Schluger NW, Cohen H, Rom WN. Outcome of MDR-TB patients, 1983–1993. Prolonged survival with appropriate therapy. *Am J Respir Crit Care Med* 1996;153:317–24.
- [4] Vilcheze C, Jacobs Jr WR. Resistance to isoniazid and ethionamide in *Mycobacterium tuberculosis*: genes, mutations, and causalities. *Microbiol Spectr* 2014;2. MGM2-0014–2013.
- [5] Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston MJ, et al. Detection of rifampicin-resistance mutations in *Mycobacterium tuberculosis*. *Lancet* 1993;341:647–50.
- [6] Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al. Rapid molecular detection of tuberculosis and rifampin resistance. *N Engl J Med* 2010;363:1005–15.
- [7] Hillemann D, Weizenegger M, Kubica T, Richter E, Niemann S. Use of the genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in *Mycobacterium tuberculosis* complex isolates. *J Clin Microbiol* 2005;43:3699–703.
- [8] Rossau R, Traore H, De Beenhouwer H, Mijs W, Jannes G, De Rijk P, et al. Evaluation of the INNO-LiPA Rif. TB assay, a reverse hybridization assay for the simultaneous detection of *Mycobacterium tuberculosis* complex and its resistance to rifampin. *Antimicrob Agents Chemother* 1997;41:2093–8.
- [9] Caws M, Duy PM, Tho DQ, Lan NT, Hoa DV, Farrar J. Mutations prevalent among rifampin- and isoniazid-resistant *Mycobacterium tuberculosis* isolates from a hospital in Vietnam. *J Clin Microbiol* 2006;44:2333–7.
- [10] WHO (ed). Molecular Line Probe Assays for rapid screening of patients at risk of multi-drug resistant tuberculosis (MDR-TB). Geneva: WHO; 2008.
- [11] Mboowa G, Namaganda C, Ssegooba W. Rifampicin resistance mutations in the 81 bp RRDR of rpoB gene in *Mycobacterium tuberculosis* clinical isolates using Xpert® MTB/RIF in Kampala, Uganda: a retrospective study. *BMC Infect Dis* 2014;14:481.
- [12] Williams DL, Waguespack C, Eisenach K, Crawford JT, Portaels F, Salfinger M, et al. Characterization of rifampin-resistance in pathogenic mycobacteria. *Antimicrob Agents Chemother* 1994;38:2380–6.
- [13] Sechi LA, Zanetti S, Sanguinetti M, Mollicotti P, Romano L, Leori G, et al. Molecular basis of rifampin and isoniazid resistance in *Mycobacterium bovis* strains isolated in Sardinia, Italy. *Antimicrob Agents Chemother* 2001;45:1645–8.
- [14] Diniz LM, Guimaraes T, Oliveira M, Pinto JA, Miranda SS. Lymphadenitis caused by infection with an isoniazid- and rifampin-resistant strain of *Mycobacterium bovis* BCG in an infant with IFN- $\gamma$ /IL-12 pathway defect. *J Bras Pneumol* 2014;40:188–92.
- [15] Hong DN, Huyen MN, Lan NT, Duong NH, Ngo VV, Ngoc DT, et al. Rifampin-resistant *Mycobacterium bovis* BCG-induced disease in HIV-infected infant, Vietnam. *Emerg Infect Dis* 2013;19:1168–70.
- [16] Wolfe JN, Blackwood-Antonation KS, Sharma MK, Cook VJ. A case of acquired rifampin resistance in *Mycobacterium bovis* bacillus Calmette–Guérin-induced cystitis: necessity for treatment guidelines. *Can J Infect Dis Med Microbiol* 2006;17:183–5.
- [17] Jacobson RR, Hastings RC. Rifampin-resistant leprosy. *Lancet* 1976;2:1304–5.
- [18] Zhang L, Namisato M, Matsuoka M. A mutation at codon 516 in the rpoB gene of *Mycobacterium leprae* confers resistance to rifampin. *Int J Lepr Other Mycobact Dis* 2004;72:468–72.
- [19] Klein JL, Brown TJ, French GL. Rifampin resistance in *Mycobacterium kansasii* is associated with rpoB mutations. *Antimicrob Agents Chemother* 2001;45:3056–8.
- [20] Reibel F, Cambau E, Aubry A. Update on the epidemiology, diagnosis, and treatment of leprosy. *Med Mal Infect* 2015;45:383–93.
- [21] Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. *Am J Respir Crit Care Med* 2007;175:367–416.
- [22] Ovchinnikov Yu A, Monastyrskaya GS, Gubanov VV, Lipkin VM, Sverdlov ED, Kiver IF, et al. Primary structure of *Escherichia coli* RNA polymerase nucleotide substitution in the beta subunit gene of the rifampicin resistant rpoB255 mutant. *Mol Gen Genet* 1981;184:536–8.
- [23] Jin DJ, Gross CA. Mapping and sequencing of mutations in the *Escherichia coli* rpoB gene that lead to rifampicin resistance. *J Mol Biol* 1988;202:45–58.
- [24] Goldstein BP. Resistance to rifampicin: a review. *J Antibiot (Tokyo)* 2014;67:625–30.
- [25] Cambau E, Viveiros M, Machado D, Raskine L, Ritter C, Tortoli E, et al. Revisiting susceptibility testing in MDR-TB by a standardized quantitative phenotypic assessment in a European multicentre study. *J Antimicrob Chemother* 2015;70:686–96.
- [26] Williamson DA, Roberts SA, Bower JE, Vaughan R, Newton S, Lowe O, et al. Clinical failures associated with rpoB mutations in phenotypically occult multidrug-resistant *Mycobacterium tuberculosis*. *Int J Tuberc Lung Dis* 2012;16:216–20.
- [27] Andres S, Hillemann D, Rusch-Gerdes S, Richter E. Occurrence of rpoB mutations in isoniazid-resistant but rifampin-susceptible *Mycobacterium tuberculosis* isolates from Germany. *Antimicrob Agents Chemother* 2014;58:590–2.
- [28] Rigouts L, Nolasco O, de Rijk P, Nduwamahoro E, Van Deun A, Ramsay A, et al. Newly developed primers for comprehensive amplification of the rpoB gene and detection of rifampin resistance in *Mycobacterium tuberculosis*. *J Clin Microbiol* 2007;45:252–4.
- [29] Sanchez-Padilla E, Merker M, Beckert P, Jochims F, Dlamini T, Kahn P, et al. Detection of drug-resistant tuberculosis by Xpert MTB/RIF in Swaziland. *N Engl J Med* 2015;372:1181–2.
- [30] Heep M, Rieger U, Beck D, Lehn N. Mutations in the beginning of the rpoB gene can induce resistance to rifamycins in both *Helicobacter pylori* and *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 2000;44:1075–7.
- [31] Miller LP, Crawford JT, Shinnick TM. The rpoB gene of *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 1994;38:805–11.
- [32] Van Deun A, Aung KJ, Hossain A, de Rijk P, Gumusboga M, Rigouts L, et al. Disputed rpoB mutations can frequently cause important rifampicin resistance among new tuberculosis patients. *Int J Tuberc Lung Dis* 2015;19:185–90.
- [33] Sandgren A, Strong M, Muthukrishnan P, Weiner BK, Church GM, Murray MB. Tuberculosis drug resistance mutation database. *PLoS Med* 2009;6:e2.
- [34] Maeda S, Matsuoka M, Nakata N, Kai M, Maeda Y, Hashimoto K, et al. Multi-drug resistant *Mycobacterium leprae* from patients with leprosy. *Antimicrob Agents Chemother* 2001;45:3635–9.
- [35] Cambau E, Bonnafous P, Perani E, Sougakoff W, Ji B, Jarlier V. Molecular detection of rifampin and ofloxacin resistance for patients who experience relapse of multibacillary leprosy. *Clin Infect Dis* 2002;34:39–45.
- [36] Yoshida S, Suzuki K, Tsuyuguchi K, Iwamoto T, Tomita M, Okada M, et al. [Detection of rpoB mutations in rifampicin-resistant *Mycobacterium kansasii*]. *Kekkaku* 2006;81:475–9.
- [37] Cambau E, Chauffour-Nevejeans A, Tejmar-Kolar L, Matsuoka M, Jarlier V. Detection of antibiotic resistance in leprosy using GenoType LepraDR, a novel ready-to-use molecular test. *PLoS Negl Trop Dis* 2012;6:e1739.
- [38] Phelan J, Coll F, McNeerney R, Ascher DB, Pires DE, Furnham N, et al. *Mycobacterium tuberculosis* whole genome sequencing and protein structure modelling provides insights into anti-tuberculosis drug resistance. *BMC Med* 2016;14:31.
- [39] Farhat MR, Sultana R, Iartchouk O, Bozeman S, Galagan J, Sisk P, et al. Genetic determinants of drug resistance in *Mycobacterium tuberculosis* and their diagnostic value. *Am J Respir Crit Care Med* 2016;194:621–30.
- [40] Honore N, Cole ST. Molecular basis of rifampin resistance in *Mycobacterium leprae*. *Antimicrob Agents Chemother* 1993;37:414–8.
- [41] Sapkota BR, Ranjit C, Neupane KD, Macdonald M. Development and evaluation of a novel multiple-primer PCR amplification refractory mutation system for the rapid detection of mutations conferring rifampicin resistance in codon 425 of the rpoB gene of *Mycobacterium leprae*. *J Med Microbiol* 2008;57:179–84.
- [42] WHO (ed). Guidelines for Global Surveillance of Drug Resistance in Leprosy. Geneva: WHO; 2009.
- [43] Cole S, Eiglmeier K, Parkhill J, James K, Thomson N, Wheeler P, et al. Massive gene decay in the leprosy bacillus. *Nature* 2001;409:1007–11.
- [44] Li W, Matsuoka M, Kai M, Thapa P, Khadge S, Hagge DA, et al. Real-time PCR and high-resolution melt analysis for rapid detection of *Mycobacterium leprae* drug resistance mutations and strain types. *J Clin Microbiol* 2012;50:742–53.
- [45] Lonnroth K, Raviglione M. The WHO's new End TB Strategy in the post-2015 era of the Sustainable Development Goals. *Trans R Soc Trop Med Hyg* 2016;110:148–50.
- [46] André EIC, Affolabi D, Alagna R, Brockmann D, de Jong BC, Cambau E, et al. Connectivity of diagnostic technologies: improving surveillance and accelerating tuberculosis elimination. *Int J Tuberc Lung Dis* 2016;20:999–1003.
- [47] Kearse M, Moir R, Wilson A, Stones-Havas S, Cheung M, Sturrock S, et al. Geneious Basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data. *Bioinformatics* 2012;28:1647–9.
- [48] El-Hajj HH, Marras SA, Tyagi S, Kramer FR, Alland D. Detection of rifampin resistance in *Mycobacterium tuberculosis* in a single tube with molecular beacons. *J Clin Microbiol* 2001;39:4131–7.

- [49] Lawn SD, Nicol MP. Xpert® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. *Future Microbiol* 2011;6:1067–82.
- [50] Hillemann D, Rusch-Gerdes S, Richter E. Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of *Mycobacterium tuberculosis* strains and clinical specimens. *J Clin Microbiol* 2007;45:2635–40.
- [51] Williamson DA, Basu I, Bower J, Freeman JT, Henderson G, Roberts SA. An evaluation of the Xpert MTB/RIF assay and detection of false-positive rifampicin resistance in *Mycobacterium tuberculosis*. *Diagn Microbiol Infect Dis* 2012;74:207–9.
- [52] Alonso M, Palacios JJ, Herranz M, Penedo A, Menendez A, Bouza E, Garcia de Viedma D. Isolation of *Mycobacterium tuberculosis* strains with a silent mutation in *rpoB* leading to potential misassignment of resistance category. *J Clin Microbiol* 2011;49:2688–90.
- [53] Mathys V, van de Vyvere M, de Droogh E, Soetaert K, Groenen G. False-positive rifampicin resistance on Xpert® MTB/RIF caused by a silent mutation in the *rpoB* gene. *Int J Tuberc Lung Dis* 2014;18:1255–7.
- [54] Ocheretina O, Byrt E, Mabou MM, Royal-Mardi G, Merveille YM, Rouzier V, et al. False-positive rifampin resistant results with Xpert MTB/RIF version 4 assay in clinical samples with a low bacterial load. *Diagn Microbiol Infect Dis* 2016;85:53–5.
- [55] Pai M, Schito M. Tuberculosis diagnostics in 2015: landscape, priorities, needs, and prospects. *J Infect Dis* 2015;211(Suppl 2):S21–8.
- [56] Kohl TA, Diel R, Harmsen D, Rothganger J, Walter KM, Merker M, et al. Whole-genome-based *Mycobacterium tuberculosis* surveillance: a standardized, portable, and expandable approach. *J Clin Microbiol* 2014;52:2479–86.
- [57] Walker TM, Kohl TA, Omar SV, Hedge J, Del Ojo Elias C, Bradley P, et al. Whole-genome sequencing for prediction of *Mycobacterium tuberculosis* drug susceptibility and resistance: a retrospective cohort study. *Lancet Infect Dis* 2015;15:1193–202.
- [58] Yuen LK, Leslie D, Coloe PJ. Bacteriological and molecular analysis of rifampin-resistant *Mycobacterium tuberculosis* strains isolated in Australia. *J Clin Microbiol* 1999;37:3844–50.
- [59] Siu GK, Zhang Y, Lau TC, Lau RW, Ho PL, Yew WW, et al. Mutations outside the rifampicin resistance-determining region associated with rifampicin resistance in *Mycobacterium tuberculosis*. *J Antimicrob Chemother* 2011;66:730–3.
- [60] Bobadilla-del-Valle M, Ponce-de-Leon A, Arenas-Huertero C, Vargas-Alarcon G, Kato-Maeda M, Small PM, et al. *rpoB* Gene mutations in rifampin-resistant *Mycobacterium tuberculosis* identified by polymerase chain reaction single-stranded conformational polymorphism. *Emerg Infect Dis* 2001;7:1010–3.
- [61] Heep M, Brandstatter B, Rieger U, Lehn N, Richter E, Rusch-Gerdes S, et al. Frequency of *rpoB* mutations inside and outside the cluster I region in rifampin-resistant clinical *Mycobacterium tuberculosis* isolates. *J Clin Microbiol* 2001;39:107–10.
- [62] McCammon MT, Gillette JS, Thomas DP, Ramaswamy SV, Graviss EA, Kreiswirth BN, et al. Detection of *rpoB* mutations associated with rifampin resistance in *Mycobacterium tuberculosis* using denaturing gradient gel electrophoresis. *Antimicrob Agents Chemother* 2005;49:2200–9.
- [63] Rigouts L, Gumusboga M, de Rijk WB, Nduwamahoro E, Uwizeye C, de Jong B, et al. Rifampin resistance missed in automated liquid culture system for *Mycobacterium tuberculosis* isolates with specific *rpoB* mutations. *J Clin Microbiol* 2013;51:2641–5.
- [64] Coll F, McNerney R, Preston MD, Guerra-Assuncao JA, Warry A, Hill-Cawthorne G, et al. Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences. *Genome Med* 2015;7:51.
- [65] Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, et al. Deciphering the biology of *Mycobacterium tuberculosis* from the complete genome sequence. *Nature* 1998;393:537–44.
- [66] Maruri F, Sterling TR, Kaiga AW, Blackman A, van der Heijden YF, Mayer C, et al. A systematic review of gyrase mutations associated with fluoroquinolone-resistant *Mycobacterium tuberculosis* and a proposed gyrase numbering system. *J Antimicrob Chemother* 2012;67:819–31.